Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/20/12 | $42,500,000 | Series B |
Casdin Capital Deerfield Management Company, L.P. Redmile Group Roche Venture Fund Third Rock Ventures WuXi Corporate Venture Fund | undisclosed |
| 01/08/13 | $13,500,000 | Series B |
Bill Gates Evan Jones Yuri Milner | undisclosed |
